Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).

Baricitinib plus corticosteroids benefits pulmonary function in SARS-CoV-2 pneumonia

5 days ago

The combination of baricitinib plus corticosteroids (BCT-CS) appears to produce meaningful improvements in pulmonary function in patients with moderate to severe SARS-CoV-2 pneumonia compared with corticosteroids alone, as shown in a study.

The analysis included 112 patients (median age, 63 years; 69.6 percent male) with arterial oxygen partial pressure (PaO2)/fraction of inspired oxygen (FiO2) of <200 mm Hg. All of them received background lopinavir/ritonavir and hydroxychloroquine; 50 patients also received corticosteroids (CS group) while 62 patients received corticosteroids together with baricitinib.

Improvements observed in oxygen saturation, assessed by pulse oximetry (SpO2)/FiO2, from hospitalization to discharge were significantly greater in the BCT-CS vs the CS group (mean difference, 49, 95 percent confidence interval [CI], 22–77; p<0.001).

Furthermore, significantly more patients in the CS than in the BCT-CS group required supplemental oxygen both at discharge (62.0 percent vs 25.8 percent; reduction of the risk, 82 percent; odds ratio [OR], 0.18, 95 percent CI, 0.08–0.43; p<0.001) and 1 month later (28.0 percent vs 12.9 percent; reduction of the risk, 69 percent; OR, 0.31, 95 percent CI, 0.11–0.86; p=0.024).

The present data indicate a possible synergistic biological effect of baricitinib when combined with corticosteroids in moderate to severe SARS-CoV-2 pneumonia. This combination appears to be a reasonably effective and safe treatment option for patients at risk of intensive care unit admission/mechanical ventilation.

More studies are needed to determine the optimal timing for starting baricitinib relative to onset of symptoms—that is whether the drug could be used earlier in patients with less severe respiratory failure—and the dose and duration of treatment.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
4 days ago
Ivermectin confers benefits in the treatment of COVID-19, with a recent study showing that its use helps reduce the risk of death especially in patients with severe pulmonary involvement.
3 days ago
Mental health comorbidities are common among patients with type 2 diabetes mellitus and may lead to worse outcomes, a recent study has found.
Roshini Claire Anthony, 13 Nov 2020

Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.

Tristan Manalac, 18 Nov 2020
The substitution of isoleucine to leucine at amino acid 97 (I97L) in the core region of the hepatitis B virus (HBV) seems to reduce its potency, decreasing the efficiency of both infection and the synthesis of the virus’ covalently closed circular (ccc) DNA, reports a new study presented at The Liver Meeting Digital Experience by the American Association for the Study of Liver Diseases (AASLD 2020).